Esperion Therapeutics, Inc. (ESPR) on Tuesday said it has agreed to acquire Corstasis Therapeutics Inc. for $75 million in upfront cash, with up to an additional $180 million tied to regulatory and commercial milestones, plus low double-digit royalties on sales of Enbumyst and related follow-on products. The company's shares were down more than 11% in pre-market trading.
The acquisition adds Enbumyst, the first and only nasal spray diuretic approved by the U.S. Food and Drug Administration for edema associated with congestive heart failure and hepatic and renal disease in adults, to Esperion's portfolio. It also brings Corstasis' subcutaneous pipeline in development, including a multidose pen injector with the potential to unlock additional market opportunities.
The transaction is expected to close in the second quarter of 2026.
"We expect that by integrating Enbumyst into our proven commercial platform, we will drive sustained double-digit growth, strengthen our leadership in cardiovascular care, and create durable value for all of our stakeholders - from patients and providers to employees and shareholders," stated Sheldon Koenig, President and Chief Executive Officer of Esperion.
Esperion shares closed at $3.27 on Monday, down 2.39%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.